Pan-resistant achromobacter xylosoxidans and stenotrophomonas maltophilia infection in cystic fibrosis does not reduce survival after lung transplantation

Transplantation

Volumn 99, Issue 10, 2015, Pages 2196-2202

  Lobo, Leonard Jason ^a   Tulu, Zeynep ^b   Aris, Robert M ^a   Noone, Peadar G ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACHROMOBACTER XYLOSOXIDANS; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; BURKHOLDERIA CENOCEPACIA; CAUSE OF DEATH; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HUMAN; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STENOTROPHOMONAS MALTOPHILIA; SURVIVAL RATE; UNITED STATES; ACHROMOBACTER DENITRIFICANS; ADOLESCENT; ADVERSE EFFECTS; ANTIBIOTIC RESISTANCE; COMPLICATION; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY; MORTALITY; MULTIDRUG RESISTANCE; PREVALENCE; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ANTIINFECTIVE AGENT;

ACHROMOBACTER DENITRIFICANS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LUNG TRANSPLANTATION; MALE; PREVALENCE; RECURRENCE; RETROSPECTIVE STUDIES; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84943165628     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000709     Document Type: Article

References (29)

1. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplan. 2012;31:1073-1086.
2. Lobo LJ, Noone PG. Respiratory infections in patients with cystic fibrosis undergoing lung transplantation. Lancet Respir Med. 2014;2:73-82.
3. Shah PD, Orens JB. Guidelines for the selection of lung-transplant candidates. Curr Opin Organ Transplant. 2012;17:467-473.
4. De Soyza A, Meachery G, Hester KL, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant. 2010;29:1395-1404.
5. Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant. 2008;8:1025-1030.
6. Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax. 2008;63:732-737.
7. Murray S, Charbeneau J, Marshall BC, Li Puma JJ. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:363-371.
8. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med. 1997;155:1699-1704.
9. Hadjiliadis D, Steele MP, Chaparro C, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant. 2007;26:834-838.
10. Dobbin C, Maley M, Harkness J, et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect. 2004;56:277-282.
11. van Duin D, van Delden C, Practice ASTIDCo. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):31-41.
12. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros. 2013; 12:482-486.
13. Hansen CR. Stenotrophomonas maltophilia: to be or not to be a cystic fibrosis pathogen. Curr Opin Pulm Med. 2012;18:628-631.
14. De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros. 2007;6:75-78.
15. Hansen CR, Pressler T, Nielsen KG, Jensen PO, Bjarnsholt T, Hoiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros. 2010;9:51-58.
16. Ronne Hansen C, Pressler T, Hoiby N, Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros. 2006;5:245-251.
17. Lambiase A, Catania MR, Del Pezzo M, et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2011;30:973-980.
18. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis. 2008;46:1121-1122; author reply 2.
19. National Committe on Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 2012; Document M100-S17.
20. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180:802-808.
21. Aaron SD. Antibiotic synergy testing should notberoutine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. Paediatr Respir Rev. 2007;8:256-261.
22. Egan TM, Detterbeck FC, Mill MR, et al. Improved results of lung transplantation for patients with cystic fibrosis. J Thorac Cardiovasc Surg. 1995;109:224-234; discussion 34-5.
23. Lobo LJ, Aris RM, Schmitz J, Neuringer IP. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant. 2013;32:70-77.
24. Smit HJ, Schreurs AJ, Van den Bosch JM, Westermann CJ.Isresection of bronchiectasis beneficial in patients with primary ciliary dyskinesia? Chest. 1996;109:1541-1544.
25. Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J. 2003;22:1007-1018.
26. Ciofu O, Hansen CR, Hoiby N. Respiratory bacterial infections in cystic fibrosis. Curr Opin Pulm Med. 2013;19:251-258.
27. Trancassini M, Iebba V, Citera N, et al. Outbreak of Achromobacter xylosoxidans in an Italian cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains. Front Microbiol. 2014;5:138.
28. Zhuo C, Zhao QY, Xiao SN. The Impact of spgM, rpfF, rmlA gene distribution on biofilm formation in Stenotrophomonas maltophilia. PLoS One. 2014;9:e108409.
29. Surette MG. The cystic fibrosis lung microbiome. Ann Am Thorac Soc. 2014;11(Suppl 1): S61-S65.